Skip NavigationSkip to Content
Return Return to Search Results

Systemic IL-15, IFN-?, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients

  1. Author:
    Bergamaschi,Cristina
    Terpos, Evangelos
    Rosati,Margherita
    Angel,Matthew
    Bear,Jenifer
    Stellas,Dimitris
    Karaliota,Sevasti
    Apostolakou, Filia
    Bagratuni, Tina
    Patseas, Dimitris
    Gumeni, Sentiljana
    Trougakos, Ioannis P
    Dimopoulos, Meletios A
    Felber,Barbara
    Pavlakis,George

  2. Author Address

    Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA., Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens 11528, Greece., Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA., Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA; Center for Cancer Research Collaborative Bioinformatics Resource, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA., Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA; Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA., Department of Clinical Biochemistry, "Aghia Sophia" Children 39;s Hospital, Athens 11527, Greece., Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Athens 15784, Greece., Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA. Electronic address: barbara.felber@nih.gov., Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA. Electronic address: george.pavlakis@nih.gov.,
    1. Year: 2021
    2. Date: Aug 10
    3. Epub Date: 2021 07 23
  2. Journal: Cell reports
    1. 36
    2. 6
    3. Pages: 109504
  4. Type of Article: Article
  5. Article Number: 109504
  6. ISSN: 2211-1247
  1. Abstract:

    Early responses to vaccination are important for shaping both humoral and cellular protective immunity. Dissecting innate vaccine signatures may predict immunogenicity to help optimize the efficacy of mRNA and other vaccine strategies. Here, we characterize the cytokine and chemokine responses to the 1st and 2nd dose of the BNT162b2 mRNA (Pfizer/BioNtech) vaccine in antigen-naive and in previously coronavirus disease 2019 (COVID-19)-infected individuals (NCT04743388). Transient increases in interleukin-15 (IL-15) and interferon gamma (IFN-gamma) levels early after boost correlate with Spike antibody levels, supporting their use as biomarkers of effective humoral immunity development in response to vaccination. We identify a systemic signature including increases in IL-15, IFN-gamma, and IP-10/CXCL10 after the 1st vaccination, which were enriched by tumor necrosis factor alpha (TNF-alpha) and IL-6 after the 2nd vaccination. In previously COVID-19-infected individuals, a single vaccination results in both strong cytokine induction and antibody titers similar to the ones observed upon booster vaccination in antigen-naive individuals, a result with potential implication for future public health recommendations.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.celrep.2021.109504
  3. PMID: 34352226
  4. PMCID: PMC8299183
  5. View record in Web of Science®
  6. WOS: 000684598900007
  7. PII : S2211-1247(21)00932-3

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel